Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase

NCT01036139 is registered in ClinicalTrials.gov with Bioprojet as lead sponsor.

NCT NCT01036139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01036139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter 12-Week Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson's Disease Followed by a 38-Week Open-label Extension Phase
Lead sponsor
Bioprojet
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2009
Completion date
August 31, 2012
Enrollment
268 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease